AR084332A1 - miRNA IN ARTROPATIA - Google Patents

miRNA IN ARTROPATIA

Info

Publication number
AR084332A1
AR084332A1 ARP110104735A ARP110104735A AR084332A1 AR 084332 A1 AR084332 A1 AR 084332A1 AR P110104735 A ARP110104735 A AR P110104735A AR P110104735 A ARP110104735 A AR P110104735A AR 084332 A1 AR084332 A1 AR 084332A1
Authority
AR
Argentina
Prior art keywords
mirna
artropatia
arthropathy
treatment
microrna
Prior art date
Application number
ARP110104735A
Other languages
Spanish (es)
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR084332A1 publication Critical patent/AR084332A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente solicitud se refiere a microRNA (miRNA), en particular mir-22, como indicador de un estado del tejido o una enfermedad tal como artrosis (OA) y como molécula diana para el descubrimiento de una sustancia para el tratamiento de una artropatía. También se proveen métodos y compuestos para investigación, análisis y/o tratamiento de una artropatía, especialmente OA.The present application relates to microRNA (miRNA), in particular mir-22, as an indicator of a state of tissue or a disease such as osteoarthritis (OA) and as a target molecule for the discovery of a substance for the treatment of arthropathy. Methods and compounds are also provided for research, analysis and / or treatment of an arthropathy, especially OA.

ARP110104735A 2010-12-17 2011-12-16 miRNA IN ARTROPATIA AR084332A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10306443 2010-12-17

Publications (1)

Publication Number Publication Date
AR084332A1 true AR084332A1 (en) 2013-05-08

Family

ID=45560875

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104735A AR084332A1 (en) 2010-12-17 2011-12-16 miRNA IN ARTROPATIA

Country Status (4)

Country Link
AR (1) AR084332A1 (en)
TW (1) TW201238973A (en)
UY (1) UY33807A (en)
WO (1) WO2012080459A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190127736A1 (en) * 2016-04-29 2019-05-02 Aptamir Therapeutics, Inc. Inhibition of mir-22 mirna by apt-110
EP3765610A4 (en) * 2018-03-14 2022-01-19 Beth Israel Deaconess Medical Center Micro-rna and obesity
WO2019229489A1 (en) * 2018-05-31 2019-12-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of mir-146a-5p and mir-186 as biomarkers of osteoarthritis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
JP2919890B2 (en) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル Single domain ligand, receptor consisting of the ligand, method for producing the same, and use of the ligand and the receptor
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ES2127948T3 (en) 1993-10-27 1999-05-01 Ribozyme Pharm Inc OLIGONUCLEOTIDES MODIFIED IN THE POSITION 2'-AMIDO AND 2'-PEPTIDE.
FR2739031B1 (en) 1995-09-27 1997-11-21 Lhd Lab Hygiene Dietetique TRANSDERMAL MATRIX SYSTEM FOR ADMINISTRATION OF AN ESTROGEN AND / OR A PROGESTIVE BASED ON STYRENE-ISOPRENE-STYRENE COPOLYMER, PREPARATION METHOD AND THERAPEUTIC USE
GB9602326D0 (en) 1996-02-06 1996-04-03 Cruachem Ltd Compounds
US5736154A (en) 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
NZ332033A (en) 1996-03-25 1999-09-29 Lohmann Therapie Syst Lts Transdermal therapeutic system (tts) with small application-area thickness and great flexibility, and production process
AUPO379596A0 (en) 1996-11-22 1996-12-19 Soltec Research Pty Ltd Percutaneous delivery system
JP2001524942A (en) 1997-02-24 2001-12-04 ティーエム テクノロジーズ，インク． Antisense oligonucleotide drugs
AU2008232316A1 (en) * 2007-03-26 2008-10-02 Newcastle Innovation Limited Therapeutic targets and molecules
US20100202973A1 (en) * 2007-05-18 2010-08-12 Karolinska Institutet Innovations Ab Microrna molecules associated with inflammatory skin disorders
WO2010056737A2 (en) * 2008-11-11 2010-05-20 Mirna Therapeutics, Inc. Methods and compositions involving mirnas in cancer stem cells

Also Published As

Publication number Publication date
TW201238973A (en) 2012-10-01
UY33807A (en) 2012-07-31
WO2012080459A1 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
CY1119056T1 (en) 2 ', 4', - DIFFluoro-2'-Methyl-Substituted Nucleoside Derivatization as HCV RNA Replication Inhibitors
CY1120204T1 (en) AMORPHIC SOLID SOLAR DISPOSAL FOR USE IN BRAND CANCER TREATMENT
CO6670585A2 (en) Promoters of apotosis n-acilsufonamides
CO6630162A2 (en) 1-amino -2-cyclopropylethylboronic acid derivatives
MX356625B (en) Oligonucleotides for making a change in the sequence of a target rna molecule present in a living cell.
GT201400063A (en) BENZILINDAZOLS REPLACED FOR USE AS INHIBITORS OF QUINASA BUB1 IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
EA201590783A1 (en) CONJUGATES FOR DELIVERY OF MEDICINES AND METHODS OF TREATMENT OF DISEASES CAUSED BY CELLS EXPRESSING PSMA
ECSP13012572A (en) ANALOGS OF NUCLEOTID REPLACED
EA201500426A1 (en) PYRROLOTRIAZINON DERIVATIVES AS PI3K INHIBITORS
CL2012002057A1 (en) Substituted macrocyclic compounds, such as hepatitis c virus inhibitors; process of preparing said compounds; pharmaceutical composition that includes them, useful as an antiviral agent.
UY33776A (en) 1-BENCILCICLOALQUILCARBOXÍLICOS ACIDS SUBSTITUTED AND ITS USE
EA201391127A1 (en) C-17 AND C-3 MODIFIED TRITERPENOIDS WITH INHIBITOR ACTIVITY OF HIV MATURATION
CU20140048A7 (en) NEW PURINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS
BR112012016376A2 (en) substituted pyrrolo-aminopyrimide compounds
BRPI0919447B8 (en) compounds derived from 1-amino-2-cyclobutylethylboronic acid, pharmaceutical composition and their use to treat cancer
NI201100082A (en) ISOINDOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER.
EA201301209A1 (en) PYRROLOTRIAZINON DERIVATIVES AS P13K INHIBITORS
CO6990719A2 (en) Derivatives of the nucleosides substituted in 4'-azido, 3'-fluoro as inhibitors of the replication of the vna rna
UA113541C2 (en) Substituted pyrrolidine-2-carboxamides
EA201491028A8 (en) METHOD OF OBTAINING SUBSTITUTED 5-FLUOR-1H-PYRAZOLOPIRIDINES
CU24263B1 (en) DERIVATIVES OF IMIDAZOPIRIDAZINAS INHIBITORS OF QUINASA AKT, USEFUL FOR THE TREATMENT OF CANCER
EA201400976A1 (en) BENZODIOXANES IN COMBINATION WITH OTHER ACTIVE MEANS TO INHIBIT LEUKOTRIEN PRODUCTION
EA201490643A1 (en) NEW BETULINIC ACID DERIVATIVES WITH ANTI-VIRUS ACTIVITY
BR112016001978A2 (en) 1,3-disubstituted cyclopentane derivatives
UY33874A (en) Substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceutical substances

Legal Events

Date Code Title Description
FA Abandonment or withdrawal